Has Kent Reifschneider received payments from drug or device companies?

Yes. Drug and device makers reported $133,154 in general payments to Kent Reifschneider across 287 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kent Reifschneider did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kent Reifschneider come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kent Reifschneider

Pediatric Endocrinology · Norfolk, VANPI 1619184710

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $81,865 of the $133,154 with a category attached, or 61.5%. Ascendis Pharma Endocrinology Inc accounts for 67.2% of it on its own, with 15 other manufacturers making up the rest. 2023 is the largest year on record at $57,034, more than ten times the $5,621 reported in 2019. Among pediatric endocrinology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$133,154in general payments, 2019–2025

Across 287 payments — averaging $463.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Ascendis Pharma Endocrinology Inc$89K
AbbVie$19K
Medtronic$9K
Endo Pharmaceuticals Inc.$6K
Sandoz$4K
Novo Nordisk$3K
plus $2K from 10 others

$63,060in research payments, 2019–2025

Across 20 payments — averaging $3153.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Ascendis Pharma Endocrinology Inc$63K

What the payments were for

Consulting fees$25,88419%
Speaking & faculty fees$81,86561%
Travel & lodging$20,56415%
Food & beverage$4,5573%
Education$2830%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Ascendis Pharma Endocrinology Inc	202	$89,494
AbbVie	22	$18,545
Medtronic(2 entities)	17	$9,062
Endo Pharmaceuticals Inc.	17	$6,416
Sandoz	1	$4,149
Novo Nordisk	10	$3,084
Vistapharm, Inc.	1	$1,540
Ultragenyx Pharmaceutical Inc.	4	$319
Biomarin Pharmaceutical Inc.	2	$155
Tandem Diabetes Care, Inc.	2	$108
Tolmar, Inc.	1	$84
Pfizer	2	$68
Dexcom, Inc.	2	$53
Tolmar Pharmaceuticals, Inc.	2	$38
Kyowa Kirin, Inc.	1	$23
Lilly USA, LLC	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$133,154 in reported general payments places this provider in the 95th percentile of 36 pediatric endocrinology providers in Virginia.

See all pediatric endocrinology providers in Virginia →

Other pediatric endocrinology in Norfolk

Eric GyuricskoNorfolk$8K
Melinda PennNorfolk$2K
Nicole NejedlyNorfolk$782
Natinder SainiNorfolk$746
Marta Satin-SmithNorfolk$661
Melissa RussellNorfolk$634
Melissa BurykNorfolk$172
Bryce NelsonRichmond$115K
David RepaskeCharlottesville$51K
Melissa SchoelwerCharlottesville$4K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →